In Belgium, 40% of people waiting for a transplant are unable to find an organ and therefore have to wait, which is why it is so important to guarantee the success of transplants. One of the major factors in failure is inappropriate dosages of the anti-rejection drug tacrolimus. University of Louvain (UCLouvain)-s Laure Elens and Laure Bindels have uncovered the influence of intestinal microbiota in the variability of the drug’s dosages. This is a world first. This discovery , published in the scientific journal Microbiome, should make it possible to better target post-transplant treatment and alleviate the resulting side effects. ...
A first for UCLouvain in the fight against organ transplant rejection
- EN - FR
Advert